Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.92 USD
+0.01 (0.96%)
Updated May 24, 2024 04:00 PM ET
After-Market: $0.92 0.00 (0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/13/24 |
---|---|
Current Quarter | -0.30 |
EPS Last Quarter | -0.27 |
Last EPS Surprise | 25.00% |
ABR | 1.33 |
Earnings ESP
|
5.88% |
---|---|
Current Year | -1.02 |
Next Year | -0.79 |
EPS (TTM) | -0.60 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 126.47M | 0.31M | 126.32M | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.30 | -0.27 | -1.02 | -0.79 |
# of Estimates | 4 | 3 | 5 | 4 |
Most Recent Consensus | NA | NA | -0.92 | NA |
High Estimate | -0.24 | -0.20 | -0.85 | -0.37 |
Low Estimate | -0.35 | -0.33 | -1.28 | -1.26 |
Year ago EPS | 0.36 | -0.37 | -0.89 | -1.02 |
Year over Year Growth Est. | -183.33% | 27.03% | -14.61% | 22.70% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 2 | 2 | 3 | 1 |
Up Last 60 Days | 2 | 2 | 3 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 1 | 2 |
Down Last 60 Days | 0 | 0 | 1 | 2 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.30 | -0.27 | -1.02 | -0.79 |
7 Days Ago | -0.30 | -0.27 | -1.02 | -0.79 |
30 Days Ago | -0.35 | -0.30 | -1.15 | -0.84 |
60 Days Ago | -0.35 | -0.30 | -1.15 | -0.84 |
90 Days Ago | -0.34 | -0.32 | -1.26 | -0.63 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.28 | -0.31 | -1.07 | -0.93 |
Zacks Consensus Estimate | -0.30 | -0.27 | -1.02 | -0.79 |
Earnings ESP | 5.88% | -12.96% | -4.25% | -17.77% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.27 | -0.32 | -0.37 | 0.36 | NA |
Estimate | -0.36 | -0.40 | -0.47 | 0.55 | NA |
Difference | 0.09 | 0.08 | 0.10 | -0.19 | 0.02 |
Surprise | 25.00% | 20.00% | 21.28% | -34.55% | 7.93% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more